Benjamin J. Ereshefsky
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Benjamin J. Ereshefsky has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
- Diaa Alrahmany
Pharmaceutical Care Department, Directorate General of Medical Supplies, Ministry of Health, Muscat 3110, Oman
2 shared publications - Islam M. Ghazi
Arnold and Marie Schwartz College of Pharmacy, Long Island University, Brooklyn, NY 11201, USA
2 shared publications Laura Pontiggia
Institute of Emerging Health Professions, Thomas Jefferson University, USA
2 shared publications- Wasim S. El Nekidy
Department of Pharmacy Services Cleveland Clinic Abu Dhabi Abu Dhabi UAE
2 shared publications Adam Wright
1 shared publication- Alexia Foy-Crowder
Prisma Health Midlands
1 shared publication
Latest Publications
- Open Access
- 2 June 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 83 (2) , e260-e269
Swab Testing to Optimize Pneumonia Treatment With Empiric Vancomycin: A Randomized Controlled Trial
Background: Fear of methicillin-resistant Staphylococcus aureus (MRSA) as a cause of community-acquired pneumonia (CAP) frequently leads to empiric vancomycin coverage. Data evaluating the use of MRSA polymerase chain reaction (PCR) nasal swab testing to guide vancomycin de-escalation is limited for patients in the intensive care unit (ICU). Methods: Swab Testing to Optimize Pneumonia Treatment With Empiric Vancomycin (STOP-Vanc) is a pragmatic, prospective, single-center, non-blinded randomized trial in which adult ICU patients with suspicion of CAP were randomized 1:1 to receive usual care either with (intervention) or without (control) the addition of MRSA nares PCR testing following ICU admission. The primary outcome was vancomycin-free hours alive, defined as the expected number of hours alive and free of vancomycin use within the first 7 days of trial enrollment as estimated using a longitudinal proportional odds state transition model adjusted for baseline covariates. Results: A total of 277 adult ICU patients were randomized. Methicillin-resistant Staphylococcus aureus PCR nasal swab testing had a negative predictive value (NPV) of 98.9% in the intervention arm. The primary endpoint, vancomycin-free hours alive, was 105.7 in the control arm and 109.7 in the intervention arm (adjusted difference, 4 hours; 95% CI, −9.5–18.2; P = .458). Conclusions: Despite MRSA PCR nasal swab testing demonstrating a high NPV in this critically ill population, MRSA PCR nasal swab testing did not decrease the duration of vancomycin use or 30-day mortality among ICU patients with suspected CAP. Additional clinician education and antimicrobial stewardship interventions might be needed to reduce vancomycin use in this patient population. Clinical Trials Registration: ClinicalTrials.gov NCT06272994 (STOP-Vanc).
- 2 June 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 83 (2) , e260-e269
Open AccessSwab Testing to Optimize Pneumonia Treatment With Empiric Vancomycin: A Randomized Controlled Trial
Background: Fear of methicillin-resistant Staphylococcus aureus (MRSA) as a cause of community-acquired pneumonia (CAP) frequently leads to empiric vancomycin coverage. Data evaluating the use of MRSA polymerase chain reaction (PCR) nasal swab testing to guide vancomycin de-escalation is limited for patients in the intensive care unit (ICU). Methods: Swab Testing to Optimize Pneumonia Treatment With Empiric Vancomycin (STOP-Vanc) is a pragmatic, prospective, single-center, non-blinded randomized trial in which adult ICU patients with suspicion of CAP were randomized 1:1 to receive usual care either with (intervention) or without (control) the addition of MRSA nares PCR testing following ICU admission. The primary outcome was vancomycin-free hours alive, defined as the expected number of hours alive and free of vancomycin use within the first 7 days of trial enrollment as estimated using a longitudinal proportional odds state transition model adjusted for baseline covariates. Results: A total of 277 adult ICU patients were randomized. Methicillin-resistant Staphylococcus aureus PCR nasal swab testing had a negative predictive value (NPV) of 98.9% in the intervention arm. The primary endpoint, vancomycin-free hours alive, was 105.7 in the control arm and 109.7 in the intervention arm (adjusted difference, 4 hours; 95% CI, −9.5–18.2; P = .458). Conclusions: Despite MRSA PCR nasal swab testing demonstrating a high NPV in this critically ill population, MRSA PCR nasal swab testing did not decrease the duration of vancomycin use or 30-day mortality among ICU patients with suspected CAP. Additional clinician education and antimicrobial stewardship interventions might be needed to reduce vancomycin use in this patient population. Clinical Trials Registration: ClinicalTrials.gov NCT06272994 (STOP-Vanc).
- Open Access
- 10 December 2025
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 5 (1)
Impact of institutional treatment guidance on the management and outcomes of Stenotrophomonas maltophilia and carbapenem-resistant Acinetobacter baumannii infections
Objective: To evaluate the impact of a guidance document on treatment decisions and clinical outcomes for infections caused by carbapenem-resistant Acinetobacter baumannii (CRAB) and Stenotrophomonas maltophilia. Design: This was a single-center, retrospective, quasi-experimental, pre- and post-intervention study. The primary outcome was adherence to antibiotic selection and dosing as recommended by the guidance document. Secondary outcomes included clinical efficacy, readmission within 90 days, all-cause 30-day mortality, 90-day microbiologic recurrence, and antibiotic-associated adverse effects. Setting: The study was conducted at a large, academic medical center in the Southeastern United States. Participants: The study included adult patients who were admitted to our institution from November 2018 to June 2024 who grew CRAB or S. maltophilia from any culture and were definitively treated. Intervention: This study included an institution specific treatment algorithm for the treatment of infections caused by resistant gram-negative organisms published on June 1 st , 2022, on our institution’s antimicrobial stewardship website. Results: Twenty-two patients with CRAB (14 pre- and 8 post-intervention) and 150 with S. maltophilia (75 pre- and 75 post-intervention) were evaluated. For CRAB, 0 (0%) patients in the pre-intervention group and 5 (62.5%) in the post-intervention group met the primary outcome ( P < .001). For S. maltophilia, 21 (28%) patients in the pre-intervention group compared to 38 (50.7%) in the post-intervention group met the primary outcome ( P < .004). Secondary outcomes did not differ significantly pre- and post-intervention. Conclusions: These findings demonstrate that implementing a local treatment guideline based on IDSA guidance may increase the utilization of evidence-based directed antimicrobial therapy for CRAB and S. maltophilia.
- 10 December 2025
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 5 (1)
Open AccessImpact of institutional treatment guidance on the management and outcomes of Stenotrophomonas maltophilia and carbapenem-resistant Acinetobacter baumannii infections
Objective: To evaluate the impact of a guidance document on treatment decisions and clinical outcomes for infections caused by carbapenem-resistant Acinetobacter baumannii (CRAB) and Stenotrophomonas maltophilia. Design: This was a single-center, retrospective, quasi-experimental, pre- and post-intervention study. The primary outcome was adherence to antibiotic selection and dosing as recommended by the guidance document. Secondary outcomes included clinical efficacy, readmission within 90 days, all-cause 30-day mortality, 90-day microbiologic recurrence, and antibiotic-associated adverse effects. Setting: The study was conducted at a large, academic medical center in the Southeastern United States. Participants: The study included adult patients who were admitted to our institution from November 2018 to June 2024 who grew CRAB or S. maltophilia from any culture and were definitively treated. Intervention: This study included an institution specific treatment algorithm for the treatment of infections caused by resistant gram-negative organisms published on June 1 st , 2022, on our institution’s antimicrobial stewardship website. Results: Twenty-two patients with CRAB (14 pre- and 8 post-intervention) and 150 with S. maltophilia (75 pre- and 75 post-intervention) were evaluated. For CRAB, 0 (0%) patients in the pre-intervention group and 5 (62.5%) in the post-intervention group met the primary outcome ( P < .001). For S. maltophilia, 21 (28%) patients in the pre-intervention group compared to 38 (50.7%) in the post-intervention group met the primary outcome ( P < .004). Secondary outcomes did not differ significantly pre- and post-intervention. Conclusions: These findings demonstrate that implementing a local treatment guideline based on IDSA guidance may increase the utilization of evidence-based directed antimicrobial therapy for CRAB and S. maltophilia.
- Open Access
- 9 October 2025
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 5 (1) , e253
Stewarding waste and antimicrobials: an assessment of chorioamnionitis regimens
Stewardship is not only about appropriate antibiotic prescribing, but also improving the utilization of resources. While multiple treatment regimens are endorsed for chorioamnionitis, some produce significantly more plastic waste than others. Ampicillin with gentamicin ± clindamycin, and vancomycin with gentamicin both create more plastic waste compared to regimens like cefoxitin, piperacillin/tazobactam, or ertapenem.
- 9 October 2025
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 5 (1) , e253
Open AccessStewarding waste and antimicrobials: an assessment of chorioamnionitis regimens
Stewardship is not only about appropriate antibiotic prescribing, but also improving the utilization of resources. While multiple treatment regimens are endorsed for chorioamnionitis, some produce significantly more plastic waste than others. Ampicillin with gentamicin ± clindamycin, and vancomycin with gentamicin both create more plastic waste compared to regimens like cefoxitin, piperacillin/tazobactam, or ertapenem.
- Open Access
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
2225. Implementing Updated Intraamniotic Infection Guidelines at a Large Academic Medical Center
Pre-existing Intraamniotic Infection Protocol Updated Intraamniotic Infection Protocol Our updated protocol for intraamniotic infection, based off of the local antibiogram. Quality Improvement Barriers and Interventions The inner behavior wheel of change was used to identify barriers to implementation. Interventions were assessed and designed using the hierarchy of intervention effectiveness. The pre-implementation survey had a 49% (61/142) response rate with 75% feeling confident ordering antibiotics for IAI ≥ 75% of the time. However, 52% reported feeling satisfied ≤ 50% of the time with the current antibiotic ordering process. Only 49.2% were aware of internal IAI guidelines. Antibiotic Use in Postpartum and Labor and Delivery Wards January 2020 through April 2023 Days of therapy (DOT) per 1000 patient days present (PDP) for aminoglycosides, ampicillin, and piperacillin-tazobactam in postpartum and labor and delivery wards 1/1/2020 through 4/2023. Cefazolin is shown as a control, as this was not a target of intervention, and remains as a standard pre-operative antibiotic. Clinical decision support tools, an example of forced function interventions, were used for successful implementation of updated antibiotic guidelines for IAI, facilitated by collaboration with stakeholders and widespread education. Further analysis of their long-term impact on antibiotic use and any potential for unintended patient harm are planned. Impact on stakeholders is being assessed via a post-implementation survey. Jennifer Thompson, MD, Up To Date Contributor: Honoraria Milner Staub, MD, MPH, Gilead: Stocks/Bonds|Johnson & Johnson: Stocks/Bonds
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
Open Access2225. Implementing Updated Intraamniotic Infection Guidelines at a Large Academic Medical Center
Pre-existing Intraamniotic Infection Protocol Updated Intraamniotic Infection Protocol Our updated protocol for intraamniotic infection, based off of the local antibiogram. Quality Improvement Barriers and Interventions The inner behavior wheel of change was used to identify barriers to implementation. Interventions were assessed and designed using the hierarchy of intervention effectiveness. The pre-implementation survey had a 49% (61/142) response rate with 75% feeling confident ordering antibiotics for IAI ≥ 75% of the time. However, 52% reported feeling satisfied ≤ 50% of the time with the current antibiotic ordering process. Only 49.2% were aware of internal IAI guidelines. Antibiotic Use in Postpartum and Labor and Delivery Wards January 2020 through April 2023 Days of therapy (DOT) per 1000 patient days present (PDP) for aminoglycosides, ampicillin, and piperacillin-tazobactam in postpartum and labor and delivery wards 1/1/2020 through 4/2023. Cefazolin is shown as a control, as this was not a target of intervention, and remains as a standard pre-operative antibiotic. Clinical decision support tools, an example of forced function interventions, were used for successful implementation of updated antibiotic guidelines for IAI, facilitated by collaboration with stakeholders and widespread education. Further analysis of their long-term impact on antibiotic use and any potential for unintended patient harm are planned. Impact on stakeholders is being assessed via a post-implementation survey. Jennifer Thompson, MD, Up To Date Contributor: Honoraria Milner Staub, MD, MPH, Gilead: Stocks/Bonds|Johnson & Johnson: Stocks/Bonds
- Open Access
- 1 November 2021
- Published by Elsevier in Journal of Infection and Public Health
- Vol. 14 (11) , 1642-1649
Risk Factors for Recurrence of Clostridioides difficile in Hospitalized Patients
- 1 November 2021
- Published by Elsevier in Journal of Infection and Public Health
- Vol. 14 (11) , 1642-1649
Open AccessRisk Factors for Recurrence of Clostridioides difficile in Hospitalized Patients
- 27 July 2020
- Published by Taylor & Francis in Journal of Chemotherapy
- Vol. 33 (3) , 165-173
Optimal vancomycin dose in the treatment of Clostridium difficile infection, antimicrobial stewardship initiative
C. difficile infections (CDI) are increasingly recognized as a leading cause of infectious diarrhea, with increasing morbidity and mortality. Treatment primarily centers around oral vancomycin treatment. A wide range of dosing regimens exist in clinical practice, with little evidence to help distinguish the therapeutic benefit between them. This is a retrospective cohort study conducted at an academic medical center that enrolled adult patients admitted with CDI. The primary outcome was a composite of complete or partial cure at the end of treatment and was assessed using a test of equivalency with a 20% equivalency limit. Subjects were divided into low dose (125 mg) or high dose (250 mg or 500 mg) of oral vancomycin dosed every 6 hours. Overall, 78 patients were included who received low dose vancomycin and 33 who received high dose. Generally, the two groups were similar, except the low dose group had significantly more leukocytosis and less ICU admission or hypotension compared to the high dose group. Equivalency between the two treatment groups was demonstrated (Absolute Risk Difference −0.022, 90% confidence interval: −0.13 to 0.18, p = 0.03). A stepwise logistic regression identified gender, baseline albumin, and ICU admission as significant predictors of the chance for complete or partial cure. No differences between groups for the secondary outcomes of 90-day readmission/recurrence, 30-day all-cause mortality, or time to resolution of diarrhea were demonstrated. Low dose oral vancomycin was demonstrated to result in equivalent outcomes compared to high dose vancomycin for the treatment of CDI.
- 27 July 2020
- Published by Taylor & Francis in Journal of Chemotherapy
- Vol. 33 (3) , 165-173
Optimal vancomycin dose in the treatment of Clostridium difficile infection, antimicrobial stewardship initiative
C. difficile infections (CDI) are increasingly recognized as a leading cause of infectious diarrhea, with increasing morbidity and mortality. Treatment primarily centers around oral vancomycin treatment. A wide range of dosing regimens exist in clinical practice, with little evidence to help distinguish the therapeutic benefit between them. This is a retrospective cohort study conducted at an academic medical center that enrolled adult patients admitted with CDI. The primary outcome was a composite of complete or partial cure at the end of treatment and was assessed using a test of equivalency with a 20% equivalency limit. Subjects were divided into low dose (125 mg) or high dose (250 mg or 500 mg) of oral vancomycin dosed every 6 hours. Overall, 78 patients were included who received low dose vancomycin and 33 who received high dose. Generally, the two groups were similar, except the low dose group had significantly more leukocytosis and less ICU admission or hypotension compared to the high dose group. Equivalency between the two treatment groups was demonstrated (Absolute Risk Difference −0.022, 90% confidence interval: −0.13 to 0.18, p = 0.03). A stepwise logistic regression identified gender, baseline albumin, and ICU admission as significant predictors of the chance for complete or partial cure. No differences between groups for the secondary outcomes of 90-day readmission/recurrence, 30-day all-cause mortality, or time to resolution of diarrhea were demonstrated. Low dose oral vancomycin was demonstrated to result in equivalent outcomes compared to high dose vancomycin for the treatment of CDI.
- 17 June 2014
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 48 (9) , 1225-1229
Fulminant Invasive Pulmonary Aspergillosis After a Near-Drowning Accident in an Immunocompetent Patient
Objective: To report on invasive aspergillosis infection in an immunocompetent adult after a near-drowning event, which allowed this pathogen to easily gain access to the human respiratory system and result in rapid, severe infection. Case Summary: A 51-year-old female developed severe pneumonia after a near-drowning accident. Two days after admission, a bronchial alveolar lavage (BAL) was performed and was positive for Aspergillus fumigatus. After a 30-day hospital course, multiple antifungals, and various routes of administration, the patient expired. Discussion: Pneumonia is particularly common because of the aspiration of contaminated water. Whereas pneumococci, staphylococci, and Gram-negative bacteria are all common pathogens for this type of infection, fungi such as Aspergillus spp can also be involved and may be life threatening. Typically, these cases are reported in individuals with an immunodeficiency such as from receipt of myelosuppressive chemotherapy, bone marrow transplants, or lung transplants. Despite initiation of an appropriate empirical antifungal regimen, the rapid recovery of A fumigatus from pulmonary alveolar lavage and BAL samples as well as extremely elevated levels of galactomannan and (1→3)-β-D glucan may have indicated an invasive fungal infection (IFI). Conclusion: IFIs are uncommon in immunocompetent adults, but in the event of a near-drowning accident, environmental fungi can gain access to the human respiratory system and result in rapid, severe infection. Based on this case and the others described, it appears that near-drowning patients need an early initial evaluation for IFI.
- 17 June 2014
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 48 (9) , 1225-1229
Fulminant Invasive Pulmonary Aspergillosis After a Near-Drowning Accident in an Immunocompetent Patient
Objective: To report on invasive aspergillosis infection in an immunocompetent adult after a near-drowning event, which allowed this pathogen to easily gain access to the human respiratory system and result in rapid, severe infection. Case Summary: A 51-year-old female developed severe pneumonia after a near-drowning accident. Two days after admission, a bronchial alveolar lavage (BAL) was performed and was positive for Aspergillus fumigatus. After a 30-day hospital course, multiple antifungals, and various routes of administration, the patient expired. Discussion: Pneumonia is particularly common because of the aspiration of contaminated water. Whereas pneumococci, staphylococci, and Gram-negative bacteria are all common pathogens for this type of infection, fungi such as Aspergillus spp can also be involved and may be life threatening. Typically, these cases are reported in individuals with an immunodeficiency such as from receipt of myelosuppressive chemotherapy, bone marrow transplants, or lung transplants. Despite initiation of an appropriate empirical antifungal regimen, the rapid recovery of A fumigatus from pulmonary alveolar lavage and BAL samples as well as extremely elevated levels of galactomannan and (1→3)-β-D glucan may have indicated an invasive fungal infection (IFI). Conclusion: IFIs are uncommon in immunocompetent adults, but in the event of a near-drowning accident, environmental fungi can gain access to the human respiratory system and result in rapid, severe infection. Based on this case and the others described, it appears that near-drowning patients need an early initial evaluation for IFI.